|
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89 Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89 conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89 Clinical research trials and A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89 medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89. A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89 Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89 clinical trial. Test subjects typically obtain the finest healthcare available for their A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89 condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89  A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89
For Condition: HIV Infections
Status: Completed
Sponsor(s): Burroughs Wellcome ,
Synopsis: To assess the safety of single oral doses of 1592U89 (abacavir succinate, ABC) administered to HIV-positive individuals. To determine the pharmacokinetics of 1592U89 after single oral doses. To determine the effects of food on the bioavailability of 1592U89.
Details: Patients are randomized in a double-blinded manner, with 12 patients entering the treatment arm and 6 patients entering the control arm. Patients in the treatment arm receive 6 single escalating doses of 1592U89 separated by at least a 6-day washout period. Patients in the control arm receive 6 single oral doses of placebo at least 6 days apart. The second and third doses of 1592U89 are equivalent. During these doses, investigators study the effects of food on the pharmacokinetics of 1592U89 by giving half of the patients the second dose with a standardized, high-fat breakfast and giving the other half the dose in a fasted state. During the third dose, patients are crossed over so that patients who received the second dose with a meal now receive it in a fasted state, and vice versa. Following the sixth dose, investigators break the blind. Patients who received 1592U89 take a seventh dose in solution form and return for follow-up at least 7 days later; patients who received placebo receive no further treatment or follow-up. Serial blood and urine samples are collected before and after each administration of 1592U89 (or placebo) for determination of plasma and urine concentrations of 1592U89, and investigators monitor patients closely for adverse events or abnormal laboratory test findings.
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Pharmacokinetics Study
Minimum Age/Maximum Age: 13 Years/55 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - HIV infection, as documented by ELISA/Western blot detection of HIV antibody, positive p24 antigen assay, positive viral culture, or other accepted technique. - Written informed consent of parent or legal guardian if under age 18. Exclusion Criteria Co-existing Condition: Excluded: - Debilitating disease, as a result of HIV or associated therapies, that, in the opinion of the investigator, might prevent the patient from completing 6-week dosing period. - Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with drug absorption. Concurrent Medication: Excluded: - Prescription or over-the-counter medication that cannot be withheld for 48 hours prior to dosing and during the 6 dosing periods. (Note: - Antiretrovirals must be withheld for 24 hours prior to dosing and during the day of dosing.) - Other investigational treatments (treatments available through a Treatment IND or other expanded access mechanism is evaluated individually in consultation with the sponsor). - Alcoholic beverages within 48 hours before dosing and during the day of dosing. - Coffee, tea, and other xanthine-containing beverages and foods on the day of dosing. Patients with the following symptoms or conditions are excluded: History of hepatitis, pancreatitis, or cardiomyopathy within the last 5 years. Risk Behavior: Excluded: Current alcohol or illicit drug use that might interfere with the patient's ability to comply with the dosing schedule and protocol evaluations, as determined by the investigator.
Total Enrollment: 18
Location and Contact Information:
Georgetown Univ Med Ctr
Washington D.C., District of Columbia, 20007
United States
Ctr for Phase I Research
Wichita, Kansas, 67214
United States
Additional Information:
Study ID Numbers: 238A; 001
Study Start Date: July 1994
Record last reviewed: October 1994
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002141
Other Hiv Infections Studies:
1. A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
2. A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2 -18 Years
3. A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
4. Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis carinii Pneumonia (PCP) in Patients with AIDS
5. A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive
Related Studies:
Other HIV Infections Clinical Trials
Other Kansas Clinical Trials
Other Wichita Clinical Trials
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89
|
|
|
|
|
|
|
|
